EX-99 2 c99478exv99.txt ANNUAL SHAREHOLDERS' MEETING SLIDES WELCOME TO THE 2005 ANNUAL MEETING OF SHAREHOLDERS Allegan, Michigan October 28, 2005 (PERRIGO LOGO) (PERRIGO LOGO) Historically. . . A generic pharmaceutical business with an OTC consumer healthcare focus (PERRIGO LOGO) (PERRIGO LOGO) TODAY - A NEW MODEL (GRAPHIC) (GRAPHIC) CHC Rx A comprehensive generic pharmaceutical business with an established OTC consumer healthcare (CHC) business and a growing Rx business (PERRIGO LOGO) FINANCIAL PERFORMANCE SALES (BAR CHART)
2000 2001 2002 2003 2004 2005 (Millions) $736 $776 $835 $834 $898 $1,024
Note: 2001 sales are adjusted. Reconciliation to GAAP results provided at www.perrigo.com/investor. (PERRIGO LOGO) FINANCIAL PERFORMANCE ADJUSTED NET INCOME [ ] ADJUSTED NET INCOME [ ] EPS (BAR CHART)
2000 2001 2002 2003 2004 2005 ADJUSTED NET INCOME (Millions) $ 15 $ 39 $ 45 $ 52 $ 71 $ 63 EPS (Dollars) $.20 $.52 $.60 $.73 $.98 $.81*
*Includes product recall charge of $6.6 million or $0.09 per share. Note: Reconciliation to GAAP results provided at www.perrigo.com/investor. (PERRIGO LOGO) 2005 HIGHLIGHTS ACCOMPLISHMENTS o Acquired Agis March 2005 o Sales up 14% or $126 million to $1,024 o Launched 9 OTC (including Nicotine Gum) and 6 Rx new products; first solid dose Rx sales CHALLENGES o Pseudoephedrine issues o Agis integration o Increasingly competitive landscape in US Generics (PERRIGO LOGO) PERRIGO - AGIS MARCH 2005 (PERRIGO LOGO) (AGIS LOGO) CHANNEL GENERIC RX RELATIONSHIPS SOLID DOSE / LIQUID API CAPABILITIES PERRIGO + AGIS EFFICIENT TOPICAL OTC MANUFACTURING, CUSTOMIZED PACKAGING RX TO OTC DIFFERENTIATED PHARMA TECHNOLOGIES
(PERRIGO LOGO) THE NEW PERRIGO MARKETS: US, Europe, Israel and Mexico BUSINESS UNITS: o CHC - store brand OTC and nutritional o Rx - topical, oral solid dose o API - active ingredients for generic pharma industry o Israeli businesses - pharmaceutical, cosmetics, toiletries (PERRIGO LOGO) THE NEW PERRIGO o 5,800 people worldwide: -- 3,200 in US -- 1,500 in Israel -- 1,100 in Europe and Mexico o 200+ life science professionals o 9 FDA inspected manufacturing facilities - 4.3 million sq. ft. (PERRIGO LOGO) STRATEGY FOR FUTURE GROWTH o Establish common brand --> Perrigo o Sustain strong base while driving generics growth o Leverage R&D capability (Rx, API) with low-cost purchasing and operations focus (store brand) across one company o Employ strong cash flows to invest in R&D o Build on customer relationships o Balance growth both internal and external (PERRIGO LOGO) (PERRIGO LOGO) DELIVERING MORE HEALTH CARE VALUE, TO MORE PLACES, IN MORE WAYS, THAN EVER BEFORE. (PERRIGO LOGO)